Abstract
The growing incidence of cancer, the toxic side-effects associated with conventional chemotherapeutic agents and the development of multidrug resistance (MDR) drive the search for novel and more effective drugs with multi-target activity and selectivity towards cancer cells. Stilbenes are a group of naturally occurring phenolic compounds of plant origin derived from the phenylpropanoid pathway that may exist as cis- or trans-isomers. Although the trans-isomer is the more common and stable configuration, resveratrol being a representative compound, cis-stilbenes are potent cytotoxic agents that bind to and inhibit tubulin polymerization, destabilizing microtubules. This review summarizes the chemistry and biological evaluation of cytotoxic stilbenes and their synthetic derivatives as promising antimitotic leads for cancer therapy, focusing on the most potent compounds, the combretastatins. Combretastatins isolated from the South African bushwillow Combretum caffrum are among the most potent antimitotic and vascular disrupting agents (VDAs) of natural origin. Preclinical studies have demonstrated their potent antitumor effects in a wide variety of tumors, both in vitro and in vivo, being currently under evaluation in phase 2 and phase 3 clinical trials for several types of solid tumors. Topics covered herein include synthetic medicinal chemistry, modes of action, structure-activity relationships (SAR), preclinical and clinical studies as VDAs in cancer therapy, either as single agents or in combination with cytotoxic anticancer drugs, antiangiogenic agents, or radiation therapy, and development of appropriate formulations based on nanocarriers (e.g., liposomes, nanoemulsions, polymeric, lipid and ceramic nanoparticles, carbon nanotubes) for improved bioavailability and targeted delivery of combretastatins to the tumor vasculature.
Keywords: Stilbenes, combretastatins, cancer, antimitotic, tubulin inhibitors, vascular disrupting agent, clinical trials, nanocarriers
Current Pharmaceutical Design
Title:Cytotoxic Stilbenes and Derivatives as Promising Antimitotic Leads for Cancer Therapy
Volume: 24 Issue: 36
Author(s): Célia Faustino, Ana P. Francisco, Vera M. S. Isca and Noélia Duarte*
Affiliation:
- Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon, Av. Prof. Gama Pinto, Lisboa 1649- 003,Portugal
Keywords: Stilbenes, combretastatins, cancer, antimitotic, tubulin inhibitors, vascular disrupting agent, clinical trials, nanocarriers
Abstract: The growing incidence of cancer, the toxic side-effects associated with conventional chemotherapeutic agents and the development of multidrug resistance (MDR) drive the search for novel and more effective drugs with multi-target activity and selectivity towards cancer cells. Stilbenes are a group of naturally occurring phenolic compounds of plant origin derived from the phenylpropanoid pathway that may exist as cis- or trans-isomers. Although the trans-isomer is the more common and stable configuration, resveratrol being a representative compound, cis-stilbenes are potent cytotoxic agents that bind to and inhibit tubulin polymerization, destabilizing microtubules. This review summarizes the chemistry and biological evaluation of cytotoxic stilbenes and their synthetic derivatives as promising antimitotic leads for cancer therapy, focusing on the most potent compounds, the combretastatins. Combretastatins isolated from the South African bushwillow Combretum caffrum are among the most potent antimitotic and vascular disrupting agents (VDAs) of natural origin. Preclinical studies have demonstrated their potent antitumor effects in a wide variety of tumors, both in vitro and in vivo, being currently under evaluation in phase 2 and phase 3 clinical trials for several types of solid tumors. Topics covered herein include synthetic medicinal chemistry, modes of action, structure-activity relationships (SAR), preclinical and clinical studies as VDAs in cancer therapy, either as single agents or in combination with cytotoxic anticancer drugs, antiangiogenic agents, or radiation therapy, and development of appropriate formulations based on nanocarriers (e.g., liposomes, nanoemulsions, polymeric, lipid and ceramic nanoparticles, carbon nanotubes) for improved bioavailability and targeted delivery of combretastatins to the tumor vasculature.
Export Options
About this article
Cite this article as:
Faustino Célia , Francisco P. Ana , Isca M. S. Vera and Duarte Noélia *, Cytotoxic Stilbenes and Derivatives as Promising Antimitotic Leads for Cancer Therapy, Current Pharmaceutical Design 2018; 24 (36) . https://dx.doi.org/10.2174/1381612825666190111123959
DOI https://dx.doi.org/10.2174/1381612825666190111123959 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and Biological Evaluation of Novel Osthol Derivatives as Potent Cytotoxic Agents
Medicinal Chemistry Drug Discovery in Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Nicotine and Gastrointestinal Disorders: Its Role in Ulceration and Cancer Development
Current Pharmaceutical Design Antiangiogenic Therapy for High-Grade Gliomas
CNS & Neurological Disorders - Drug Targets Challenges and Opportunities from Basic Cancer Biology for Nanomedicine for Targeted Drug Delivery
Current Cancer Drug Targets Segmentation and Classification of Lung Cancer: A Review
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Labeling Strategies of Peptides with 18F for Positron Emission Tomography
Current Topics in Medicinal Chemistry Transductional Targeting of Adenoviral Cancer Gene Therapy
Current Gene Therapy Thermodynamic and Kinetic Aspects Involved in the Development of Nanocarriers and Drug Delivery Systems Based on Cationic Biopolymers
Current Pharmaceutical Design Recent Trends in the Pharmacological Activity of Isoprenyl Phenolics
Current Medicinal Chemistry Quantifying Risk: The Role of Absolute and Relative Measures in Interpreting Risk of Adverse Reactions from Product Labels of Antipsychotic Medications
Current Drug Safety Application of Mesenchymal Stem Cells in the Targeted Gene Therapy for Gastric Cancer
Current Stem Cell Research & Therapy Removing Protein Aggregates: The Role of Proteolysis in Neurodegeneration
Current Medicinal Chemistry Clinical Value of 99mTc-octreotide Scintigraphy and Planar X-ray Mammography for the Diagnosis of Breast Cancer
Current Medical Imaging Current Advances in the Identification and Characterization of Putative Drug and Vaccine Targets in the Bacterial Genomes
Current Topics in Medicinal Chemistry Nanoparticles Based on Plasma Proteins for Drug Delivery Applications
Current Pharmaceutical Design Trisodium Citrate Dihydrate-Catalyzed One-Pot Three-component Synthesis of Biologically Relevant Diversely Substituted 2-Amino-3-Cyano-4-(3- Indolyl)-4H-Chromenes under Eco-Friendly Conditions
Current Green Chemistry Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer
Current Radiopharmaceuticals Intracellular Trafficking Mechanism and Cytosolic Protein Interactions of a Non Viral Gene Delivery Vector: Studies Based on Transferrin Conjugated Pullulan-PEI
Current Nanoscience An Overview of Phytotherapeutic Approaches for the Treatment of Benign Prostatic Hyperplasia
Mini-Reviews in Medicinal Chemistry